Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Pompe Disease Treatment Market

Pompe Disease Treatment Market Share

Report ID: GMI8315
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Pompe Disease Treatment Market Share

The pompe disease treatment industry is highly competitive, featuring pharmaceutical and biotechnology firms along with research institutions. The companies are actively focusing on innovative therapies and improve patient care by developing and commercializing novel treatment approaches for Pompe disease patients.

Pompe Disease Treatment Market Companies

Prominent players operating in the pompe disease treatment industry are as mentioned below:

Abeona Therapeutics Inc.
Amicus Therapeutics, Inc.
Aro Biotherapeutics Company
Audentes Therapeutics (Astellas Pharma Inc.)
Bayer AG
F. Hoffmann-La Roche Ltd.
Genethon
Maze Therapeutics
M6P Therapeutics
Oxyrane
Sanofi
Valerion Therapeutics

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of pompe disease treatment reached USD 1.6 billion in 2023 and is set to cross USD 2.3 billion by 2032, due to the escalated burden of Pompe disease, leading to increased demand for effective treatments.

Monotherapy segment is expected to record a CAGR of 4.4% over 2024 and 2032, due to its simplicity and effectiveness in managing Pompe disease.

North America market accounted for a revenue share of 37.8% in 2023, driven by the proliferation of novel drug launches, a robust presence of pharmaceutical companies in the region, and increased R&D investments.

Abeona Therapeutics Inc., Amicus Therapeutics, Inc., Aro Biotherapeutics Company, Audentes Therapeutics (Astellas Pharma Inc.), Bayer AG, F. Hoffmann-La Roche Ltd., Genethon, Maze Therapeutics, M6P Therapeutics, Oxyrane, Sanofiare some of the major industry contenders.